References
- Carrier M, Le Gal G, Tay J, et al. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost. 2011;9:653–663.
- Hemker HC, Giesen P, Al Dieri R, et al. Béguin, Calibrated automated thrombin generation measurement in clotting plasma, Pathophysiol. Pathophysiol Haemos Thromb. 2003;33:4–15.
- Hron G, Kollars M, Binder BR, et al. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA. 2006;296:397–402.
- Besser M, Baglin C, Luddington R, et al. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost JTH. 2008;6:1720–1725.
- Leiba M, Malkiel S, Budnik I, et al. Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients. Blood Cells Mol Dis. 2017;65:1–7.
- Gracheva MA, Urnova ES, Sinauridze EI, et al. Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulabilityin patients with multiple myeloma. Leuk Lymphoma. 2015;56:3418–3425.
- Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414–423.
- Palmaro A, Rougé-Bugat ME, Gauthier M, et al. Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database. Pharmacoepidemiol Drug Saf. 2017;26:578–586.
- Al-Ani F, Bermejo JM, Mateos MV, et al. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - a systematic review. Thromb Res. 2016;141:84–90.
- Larocca A, Cavallo F, Bringhen S, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012;119:933–939.
- Egan K, Cooke N, Dunne E, et al. Platelet hyporeactivity in active myeloma. Thromb Res. 2014;134:747–749.